Sands Capital Ventures
VC Fund
Arlington, United States
Sands Capital Ventures is a VC fund in Arlington focused on Health Care and Biotechnology. Sands Capital is an active, long-term investor in innovative growth businesses. The approach combines rigorous fundamental analysis with inspired thinking to seek out businesses that are creating the future. They operate through two affiliates: Sands Capital Management, which focuses on investing in companies in the public market, and Sands CapitalVentures, which focuses on investing in companies in the private market. By enabling clients to participate in the growth of these businesses, its mission is to add value and enhance their wealth with prudence over time.
- Total investments:
- 213
- Last investment:
- Lead investor:
- 24%
- Fund size:
- $1.1B
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Sands Capital Ventures invests in
Stages Sands Capital Ventures invests in
Countries Sands Capital Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 19 contacts → | |||
Round size
- Series A
- $7M–$50M
- Series B
- $12M–$108M
- Series C
- $20M–$220M
Investment Focus
Industry
- Health Care 40 (19%)
- Biotechnology 37 (17%)
- Software 25 (12%)
- Artificial Intelligence 22 (10%)
- Medical 20 (9%)
Stage
- Series B 33 (15%)
- Series A 32 (15%)
- Series C 26 (12%)
- Series D 24 (11%)
- Series E 18 (8%)
Country
- United States 98 (46%)
- United Kingdom 9 (4%)
- India 4 (2%)
- Canada 3 (1%)
- Israel 2 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Barron B. Martin, Jr.
Sr. Research Associate
|
Sr. Research Associate | Total investments: 4 | Find email | |
Christopher Eng
Principal
|
Principal | Total investments: 3 | Find email | |
Frank M. Sands, Jr.
Director
|
Director | Total investments: 4 | Find email | |
Mark McGovern
Venture Partner
|
Venture Partner | Total investments: 1 | Find email | |
Michael J. Ginder
Partner
|
Partner | Total investments: 3 | Find email | |
| See all 19 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Base Power provides home battery systems, retail electricity services, and energy management solutions for residential customers. The company installs battery storage systems that provide backup power during outages and help manage electricity usage. Its platform combines distributed battery storage with electricity services to support home energymanagement and grid operations. | $1B / Series D / Aug 03, 2026 | ||
| K2 Space builds and supplies high-power satellite platforms designed for diverse orbital missions using vertically integrated hardware and manufacturing processes. The company focuses on developing large “Mega Class” satellites with enhanced power, payload capacity, and propulsion systems to support communications, sensing, and other spaceapplications. K2 Space offers engineered solutions for factory assembly, launch stacking, and orbital operations that aim to serve Low Earth Orbit, Medium Earth Orbit, and Geostationary missions. Its offerings include resilient spacecraft designs tailored to withstand harsh space environments and support scalable constellation deployments. | $500M / Series D / Jul 30, 2026 | ||
| Baseten provides a platform for training, deploying, and serving artificial intelligence models in production environments. It supports open-source, fine-tuned, and custom models, converting them into API endpoints with capabilities such as autoscaling, observability, and optimized model serving. The platform manages infrastructure componentsincluding containerization, GPU scheduling across multiple cloud providers, and performance optimizations to support large-scale inference workloads. Baseten also offers preconfigured model APIs and deployment options that can run either on its managed cloud service or within a customer's own environment. Its tools are designed to help developers build, manage, and scale AI applications while maintaining flexibility in how models are hosted and executed. | $1.5B / Series F / Jun 22, 2026 | ||
| Ramp is a financial technology company that develops software for corporate spend management, finance operations, and business payments. The company provides an integrated platform that combines corporate cards, expense management, accounts payable automation, procurement, travel booking, reimbursements, treasury services, and accountingautomation. Its software is designed to help organizations manage business spending, streamline financial workflows, and centralize finance operations within a single system. The platform enables businesses to issue and manage corporate cards, process vendor payments, track expenses, handle employee reimbursements, and automate accounting processes. It also incorporates artificial intelligence capabilities that assist with receipt matching, transaction categorization, policy enforcement, approval workflows, and financial reporting. These features are intended to reduce manual administrative work and improve visibility into organizational spending. | $750M / Series F / Jun 04, 2026 | ||
| RevEng.AI is a cyber security and artificial intelligence company that helps organizations understand their cyber security supply chain. RevEng.ai identifies fundamental components of closed-source program binaries and generates real-valued vector embeddings for each component. | $15M / Series A / May 27, 2026 | ||
| Cnuic Technologies has developed a working prototype of a completely new type of photolithography device. | $3M / Pre-Seed / Apr 28, 2026 | ||
| AI-Enabled Coding for Medical Billing Teams | $16M / Series A / Apr 15, 2026 | ||
| Acumen is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target amyloid-beta oligomers, (AβOs), which Acumen believes to be a key underlying cause of Alzheimer’s disease, or AD. Acumen is currently focused on advancing a targeted immunotherapy drug candidate, ACU193, to establish proof of mechanism inearly AD patients. Acumen initiated its Phase 1 clinical trial of ACU193 in the second quarter of 2021 with the objective to evaluate its safety and tolerability and explore its pharmacokinetics and target engagement. This trial is currently enrolling patients with mild cognitive impairment and mild dementia due to AD. ACU193 Phase 1 data intended to evaluate safety and tolerability and demonstrate clinical proof of mechanism are expected by year end 2022. | $35.8M / Post-IPO Equity / Mar 16, 2026 | ||
| Legora develops an artificial intelligence software platform designed to support legal professionals in tasks such as document review, drafting, and legal research. The platform analyzes large volumes of legal documents, identifies relevant clauses or issues, and suggests edits or language based on prior legal materials and user inputs. Itintegrates with commonly used legal and document management tools, allowing lawyers to work within applications such as word processing systems and internal knowledge repositories. Legora also enables users to search legal databases and internal firm documents from a unified workspace, helping legal teams access information and precedents within a single interface. The system supports collaboration by allowing multiple users to review materials, generate summaries, and organize findings during legal workflows. Its software is used by law firms and in-house legal teams to manage research, document preparation, and information analysis associated with legal matters. | $550M / Series D / Mar 10, 2026 | ||
| Anthropic develops artificial intelligence tools and research initiatives focused on creating AI systems and models for business and research use. The company produces the Claude family of AI products, including conversational and coding assistants, integrations with productivity applications, and developer APIs that organizations can deploy for automation, information retrieval, and task workflows. It also engages in systematic research and analysis of AI behavior, safety methods, and policy issues to inform product design and external stakeholders. Beyond product development, Anthropic generates documented insights and collaborates with academic, civil society, and industry groups to explore implications of AI on economic and societal systems. These efforts aim to connect foundational research with practical AI applications in enterprise environments. | $30B / Series G / Feb 12, 2026 | ||
| See all 213 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Sands Capital Ventures invest in?
Sands Capital Ventures invests primarily in Health Care, Biotechnology and Software startups, most often at Series B and Series A stage. Most of the 213 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Sands Capital Ventures's check size?
Sands Capital Ventures typically joins rounds of $7M–$50M at Series A, $12M–$108M at Series B and $20M–$220M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sands Capital Ventures participates in.
How do I contact Sands Capital Ventures?
Public channels for Sands Capital Ventures include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Sands Capital Ventures?
The team at Sands Capital Ventures includes Barron B. Martin, Jr. (Sr. Research Associate), Christopher Eng (Principal) and Frank M. Sands, Jr. (Director), among 19 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
